Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6517-6528

  Groeneweg, Jolijn W ^a,b   Hernandez, Silvia F ^a,b   Byron, Virginia F ^a   DiGloria, Celeste M ^a   Lopez, Hector ^a   Scialabba, Vanessa ^a   Kim, Minji ^a   Zhang, Ling ^a   Borger, Darrell R ^a   Tambouret, Rosemary ^a,b   Foster, Rosemary ^a,b   Rueda, Bo R ^a,b   Growdon, Whitfield B ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENE AMPLIFICATION; HER2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR XENOGRAFT; UTERINE SEROUS CARCINOMA; UTERUS CARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CYSTADENOCARCINOMA, SEROUS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME; UTERINE NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; DISEASE MODELS, ANIMAL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMANS; MICE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRASTUZUMAB; TUMOR BURDEN; UTERINE NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919766569     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1647     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: Cancer J Clin 2012;62:10-29.
2. Keys HM, Roberts JA, Brunetto V.L., Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744-51.
3. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355: 1404-11.
4. Schwartz PE. The management of serous papillary uterine cancer. Curr Opin Oncol 2006;18:494-9.
5. Rose PG. Endometrial carcinoma. N Engl J Med 1996;335:640-9.
6. Fleming GF, Brunetto VL, Cella D, Look K.Y., Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22: 2159-66.
7. Humber CE, Tierney JF, Symonds R.P., Collingwood M., Kirwan J, Williams C, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007;18:409-20.
8. Hamilton CA, Cheung MK, Osann K, Chen L., Teng NN, Longacre TA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006;94:642-6.
9. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
10. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
11. Hechtman JF, Polydorides AD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med 2012;136:691-7.
12. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009;27:5838-47.
13. Baselga J. Treatment of HER2-overexpressing breast cancer. Ann Oncol 2010;21:vii36-vii40.
14. Blackwell KL, Burstein HJ, Storniolo A.M., Rugo HS, Sledge G, Aktan G, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012;30:2585-92.
15. Swain SM, Kim SB, Cortes J, Ro J., Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14:461-71.
16. Baselga J, Bradbury I, Eidtmann H., Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633-40.
17. Krop IE, LoRusso P, Miller K.D., Modi S., Yardley D, Rodriguez G, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012;30:3234-41.
18. Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, et al. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol 2005;98:24-30.
19. Slomovitz BM, Broaddus RR, Burke T.W., Sneige N., Soliman PT, Wu W, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004;22:3126-32.
20. Buza N, English DP, Santin A.D., Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol 2013;26:1605-12.
21. El-Sahwi K., Bellone S, Cocco E., Cargnelutti M, Casagrande F, Bellone M., et al. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer 2010;102: 134-43.
22. Galsky MD, Von Hoff DD, Neubauer M, Anderson T, Fleming M., Nagarwala Y, et al. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs 2012;30:695-701.
23. Leslie KK, Sill MW, Lankes H.A., Fischer EG, Godwin AK, Gray H, et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 2012;127:345-50.
24. Fleming GF, Sill MW, Darcy K.M., McMeekin DS, Thigpen JT, Adler LM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010;116:15-20.
25. Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest 2011;121:3797-803.
26. Pazo Cid R.A., Anton A. Advanced HER2-positive gastric cancer: current and future targeted therapies. Crit Rev Oncol Hematol 2013; 85:350-62.
27. Santin AD. Letter to the Editor referring to the manuscript entitled: "Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study" recently reported by Fleming et al., (Gynecol Oncol., 116;15-20;2010). Gynecol Oncol 2010;118:95-6.
28. Prat A, Baselga J. Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapyfree therapy. J Clin Oncol 2013;31:1703-6.
29. English DP, Roque DM, Carrara L, Lopez S., Bellone S, Cocco E, et al. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecol Oncol 2013;131:753-8.
30. Morgan J, Hoekstra AV, Chapman-Davis E, Hardt J.L., Kim JJ, Buttin BM. Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma. Gynecol Oncol 2009;114:293-8.
31. Dias-Santagata D., Akhavanfard S, David S.S., Vernovsky K., Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010;2:146-58.
32. Groeneweg JW, Hall TR, Zhang L, Kim M, Byron VF, Tambouret R, et al. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model. Gynecol Oncol 2014; 133:607-15.
33. English DP, Bellone S, Cocco E., Bortolomai I, Pecorelli S, Lopez S., et al. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Am J Obstet Gynecol 2013;209:465 e1-9.
34. Thibault C, Khodari W, Lequoy M., Gligorov J, Belkacemi Y. HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: a review. Crit Rev Oncol Hematol 2013;88:123-33.
35. Kumler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev 2014;40:259-70.
36. Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M., Siegel ER, et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 2005;104:1391-7.
37. El-Sahwi K.S., Schwartz PE, Santin AD. Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Rev Anticancer Ther 2012;12:41-9.
38. Buza N, Roque DM, Santin AD. HER2/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med 2014;138:343-50.
39. Santin AD, Bellone S, Siegel E.R., Palmieri M., Thomas M, Cannon MJ, et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol 2005;192:813-8.
40. Khasraw M, Bell R. Primary systemic therapy in HER2-amplified breast cancer: a clinical review. Expert Rev Anticancer Ther 2012;12: 1005-13.
41. Kondo N, Tsukuda M, Ishiguro Y., Kimura M, Fujita K, Sakakibara A., et al. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 2010;23:957-63.
42. Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I., Redrado M, et al. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer 2010;10:188.
43. Garrett JT, Sutton CR, Kuba M.G., Cook RS, Arteaga CL. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res 2013;19:610-9.
44. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009;15:7479-91.
45. Wilken JA, Maihle NJ. Primary trastuzumab resistance: new tricks for an old drug. Ann N Y Acad Sci 2010;1210:53-65.
46. Scaltriti M, Rojo F, Ocana A., Anido J, Guzman M, Cortes J., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628-38.
47. Han SW, Cha Y, Paquet A., Huang W, Weidler J, Lie Y., et al. Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. PLoS ONE 2012;7:e39943.
48. Arribas J, Baselga J, Pedersen K., Parra-Palau JL. p95HER2 and breast cancer. Cancer Res 2011;71:1515-9.
49. Todeschini P, Cocco E, Bellone S., Varughese J, Lin K, Carrara L., et al. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. Br J Cancer 2011;105:1176-82.
50. Scaltriti M, Verma C, Guzman M., Jimenez J, Parra JL, Pedersen K, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009;28:803-14.